About Us

Pacific Marine Biotech (PMB) is a United States-based biotech company founded in December 2021 by Samuel Grant and Alan Temkin. Our team’s mission is to provide a safe and natural treatment solution for DIPG and Glioblastoma that restores Quality of Life by securing FDA drug approval for Immune12.

PMB’s immediate objective is to create partnerships with leading healthcare institutions in the United States for the purpose of conducting clinical trials on Immune12. We envision a future in which we can positively change the way cancer is treated, rewriting the narrative for thousands of cancer patients every year and for the betterment of communities around the world.

Learn more below…

Our History

It started with an act of kindness. In 1962, our founder’s father, Sam Grant Sr., was diagnosed with terminal stomach cancer. After moving his family to northern Australia to enjoy what would have been his last few months, he met a fisherman whose boat had broken down on the shore. Sam’s family went to work and repaired his boat…

Our Leadership Team

Our international leadership team brings decades of experience to PMB. Our breadth of skills, from science, medicine, research, finance, law and business, provide the foundation for our mission.

Our Mission

Following Hippocrates’ Primum non nocera, “First, do no harm,” we build on traditional treatment methods to offer hope for cancer patients and their families. Proper care and treatment should not only extend your life, it should also improve your quality of life and well-being. That’s why we drive the research of a holistic, all-natural, and non-toxic treatment option, Immune¹², and provide support to the entire care team.